Maximize Your Early Phase Oncology Assets with a Successful Drug Development Plan

Webcast

Wed, Jul 27, 2022 10:00 AM SGT (Tue, Jul 26, 2022 10:00 PM EDT) Join this webinar to learn how JAPAC IQVIA Biotech leverages data and expertise to support your strategic drug development for early oncology assets to ensure your success.

Register Free: http://www.appliedclinicaltrialsonline.com/act_w/plan

Event overview:

The drug development landscape in Asia Pacific is accelerating more than ever before. Emerging biotech companies now face multiple hurdles in the clinical development process – from learning to prioritize the right target indication, effectively designing robust clinical study program with integration of right biomarkers ultimately seeking compressed development timelines.
With increasing trial complexity and decreasing success rate for oncology assets in the clinical productivity index, it is critical for small sponsors to identify the right target disease indication and consider the appropriate biomarker strategies right from the start of your early clinical development plan.
Join this webinar to learn how JAPAC IQVIA Biotech leverages data and expertise to support your strategic drug development for early oncology assets to ensure your success.

3 Key take-aways

  • Learn how Indication Prioritization analysis can increase the return of investment of your oncology assets
  • Gain insights into how IQVIA Biotech can support your oncology early assets through our CDP oncology program
  • Learn how to integrate biomarker strategies in the framework of clinical trial and laboratory operations and global scalability

Speakers

Christopher Hart
Senior Director
Drug Development Lead Planning and Design Operations
IQVIA

Christopher Hart, senior therapeutic strategy director, strategic drug development, IQVIA.
Chris leads the data science team within strategic drug development at IQVIA. He joined IQVIA in 2019 and has more than 20 years of pharmaceutical development experience.
Chris & his team use IQVIA’s Connected Intelligence as part of a multidisciplinary strategic drug development team to help biopharmaceutical companies with some of their most important decisions: which indications to prosecute; what target product profile to use; and how best to achieve an optimal label.
He started his industry career as a statistical programmer at AstraZeneca. His experience includes several submissions, multiple therapeutic areas, all phases of clinical development, and numerous leadership roles.

Eric Groves
Vice President
Strategic Drug Development, Design and Delivery Innovation
IQVIA

Dr Groves is Board Certified, in oncology and internal medicine with 32+ years of experience in drug development as corporate officer/senior manager, clinician and researcher.
Noteworthy are his accomplishments in clinical and preclinical development, research and general management, for agents with oncologic, infectious disease, immunologic, dermatologic and pain therapy applications. At IQVIA, Dr Groves has provided drug development guidance to a wide variety of clients both small biotech and large pharma.
Dr. Groves received his B.S. degree from Massachusetts Institute of Technology and his Ph.D. in physics from the University of Pennsylvania. He earned his M.D. at the University of Miami and completed an internal medicine residency followed by a National Cancer Institute oncology fellowship.

Bradley Smith
Vice President
Strategic Drug Development, Translational Medicine
IQVIA
Dr. Smith is currently the Vice President of Translational Medicine in the Strategic Drug Development Group within IQVIA. In this position, Dr. Smith leads precision medicine and companion diagnostic strategy and planning client interactions including clinical, laboratory, corporate and commercial projects.
He brings more than 20 years of experience in biological research in academia and biotechnology including 13 years in planning and design of clinical studies in drug development. Prior to IQVIA, Dr. Smith spent 10 years at Cell Signaling Technology, responsible for technical and corporate development of biomarker and diagnostic businesses.
He is the author of multiple basic research, translational medicine and clinical publications and patents and has a Ph.D. from Stanford University and held post-doctoral fellowships at Stanford University and UCSF.

Megan McCausland
Scientific Advisor, Flow Cytometry
Q2 Solutions

Megan McCausland is the Scientific Advisor for Flow Cytometry at Q2 Solutions, where she serves as a flow cytometry subject matter expert, engaging with clients to design state-of-the-art high-parameter panels to support global clinical trials across broad portfolio of indications.
She joined Q2 in 2013 as an Assay Development Scientist in the Translation Science Laboratory where she was responsible for development, validation and global implementation of multi-parameter flow cytometry assays. 
More recently, she has led the global deployment of the Cytek Aurora spectral cytometer as Q2 Solutions’ choice for their next generation flow cytometry platform. 
Prior to joining Q2 Solutions, Megan spent 13 years in academia studying the generation and maintenance of immune memory at Emory University and La Jolla Institute for Immunology. She holds a BS in Biology from James Madison University.

Register Free: http://www.appliedclinicaltrialsonline.com/act_w/plan